5-Carbethoxy-2-(N-carbophenoxy-N-methylamino)methylthiazole | 78442-10-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-Carbethoxy-2-(N-carbophenoxy-N-methylamino)methylthiazole
• 英文别名: ethyl 2-[[methyl(phenoxycarbonyl)amino]methyl]-1,3-thiazole-5-carboxylate
• CAS: 78442-10-1
• 化学式: C₁₅H₁₆N₂O₄S
• 分子量: 320.369
• InChiKey: FEDUVYHGCSHJFP-UHFFFAOYSA-N

物化性质

• 沸点：
  442.3±41.0 °C(Predicted)
• 密度：
  1.288±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  22
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  97
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  (N-carbophenoxy-N-methylamino)thioacetamide 、 (氯甲酰基)乙酸乙酯 在 two 、 disodium;carbonate 、 水 、 Sodium sulfate-III 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 3.5h， 生成 5-Carbethoxy-2-(N-carbophenoxy-N-methylamino)methylthiazole
  参考文献：
  名称：

  Chemical compounds

  摘要：

  组成式为##STR1##的组胺H.sub.2-拮抗剂，其中p为1或2；R.sup.1为羟基，氨基，取代氨基或通过其氮原子连接的5-至9-成员完全饱和的含氮杂环；m为0至2的整数；n为2至4的整数；Z为硫，氧或亚甲基；而A为可选取代的苯基，咪唑基，噻唑基，异噻唑基，噁唑基，异噁唑基，三唑基，噻二唑基，氧杂噻二唑基，呋喃基，噻吩基或吡啶基环；以及其非毒性药学上可接受的盐，水合物，溶剂合物或N-氧化物是新的抗溃疡剂。公开了其中间体和制备方法。

  公开号：

  US04380638A1

文献信息

• Thiadiazole histamine H.sub.2 -antagonists
  申请人：Bristol-Myers Company

  公开号：US04471122A1

  公开（公告）日：1984-09-11

  Histamine H.sub.2 -antagonists of the formula ##STR1## wherein p is 1 or 2; R.sup.1 is hydroxy, amino, substituted amino or a 5- to 9-membered fully saturated nitrogen-containing heterocyclic ring attached via its nitrogen atom; m is an integer of from 0 to 2; n is an integer of from 2 to 4; Z is sulfur, oxygen or methylene; and A is an optionally substituted phenyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, furyl, thienyl or pyridyl ring; and nontoxic pharmaceutically acceptable salts, hydrates, solvates or N-oxides thereof are novel anti-ulcer agents. Intermediates and processes for their preparation are disclosed.

  组织名称为##STR1##的组织胺H.sub.2-拮抗剂，其中p为1或2；R.sup.1为羟基、氨基、取代氨基或通过其氮原子连接的含氮5-至9-成员完全饱和的杂环环；m为0到2的整数；n为2到4的整数；Z为硫、氧或亚甲基；A为可选择取代的苯基、咪唑基、噻唑基、异噻唑基、噁唑基、异噁唑基、三唑基、噻二唑基、噁二唑基、呋喃基、噻吩基或吡啶基环；以及其新型抗溃疡剂的无毒药用盐、水合物、溶剂合物或N-氧化物。披露了其制备的中间体和方法。
• Histamine H.sub.2 -antagonists
  申请人：Bristol-Myers Company

  公开号：US04510309A1

  公开（公告）日：1985-04-09

  Histamine H.sub.2 -antagonists of the formula ##STR1## wherein p is 1 or 2; R.sup.1 is hydroxy, amino, substituted amino or a 5- to 9-membered fully saturated nitrogen-containing heterocyclic ring attached via its nitrogen atom; m is an integer of from 0 to 2, n is an integer of from 2 to 4; Z is sulfur, oxygen or methylene; and A is an optionally substituted phenyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, furyl, thienyl or pyridyl ring; and nontoxic pharmaceutically acceptable salts, hydrates, solvates or N-oxides thereof are novel anti-ulcer agents. Intermediates and processes for their preparation are disclosed.

  组式为##STR1##的组胺H.sub.2-拮抗剂，其中p为1或2；R.sup.1为羟基、氨基、取代氨基或通过其氮原子连接的含氮杂环环的5到9成员完全饱和的环；m为0到2的整数，n为2到4的整数；Z为硫、氧或亚甲基；A为可选取代的苯基、咪唑基、噻唑基、异噻唑基、噁唑基、异噁唑基、三唑基、噻二唑基、噁二唑基、呋喃基、噻吩基或吡啶基环；以及其非毒性药用可接受的盐、水合物、溶剂合物或N-氧化物是新型抗溃疡药物。公开了其制备的中间体和方法。
• Substituted 1,2,5-thiadiazole derivatives
  申请人：Bristol-Myers Company

  公开号：US04380639A1

  公开（公告）日：1983-04-19

  Histamine H.sub.2 -antagonists of the formula ##STR1## wherein p is 1 or 2; R.sup.1 is hydroxy, amino, substituted amino or a 5- to 9-membered fully saturated nitrogen-containing heterocyclic ring attached via its nitrogen atom; m is an integer of from 0 to 2; n is an integer of from 2 to 4; Z is sulfur, oxygen or methylene; and A is an optionally substituted phenyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, furyl, thienyl or pyridyl ring; and nontoxic pharmaceutically acceptable salts, hydrates, solvates or N-oxides thereof are novel anti-ulcer agents. Intermediates and processes for their preparation are disclosed.

  该专利涉及一种组成式为##STR1##的组织胺H.sub.2-拮抗剂，其中p为1或2；R.sup.1为羟基，氨基，取代氨基或通过其氮原子连接的5-至9-成员完全饱和的含氮杂环；m为0到2的整数；n为2到4的整数；Z为硫，氧或亚甲基；而A为可选的取代苯基，咪唑基，噻唑基，异噻唑基，噁唑基，异噁唑基，三唑基，噻二唑基，氧杂二唑基，呋喃基，噻吩基或吡啶基；以及其非毒性医药上可接受的盐，水合物，溶剂合物或N-氧化物是新的抗溃疡剂。还公开了其中间体和制备方法。
• 3,4-Disubstituted-1,2,5-thiadiazole-1-oxide compounds
  申请人：Bristol-Myers Company

  公开号：US04374248A1

  公开（公告）日：1983-02-15

  Histamine H.sub.2 -antagonists of the formula ##STR1## wherein p is 1 or 2; R.sup.1 is hydroxy, amino, substituted amino or a 5- to 9-membered fully saturated nitrogen-containing heterocyclic ring attached via its nitrogen atom; m is an integer of from 0 to 2; n is an integer of from 2 to 4; Z is sulfur, oxygen or methylene; and A is an optionally substituted phenyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, furyl, thienyl or pyridyl ring; and nontoxic pharmaceutically acceptable salts, hydrates, solvates or N-oxides thereof are novel anit-ulcer agents. Intermediates and processes for their preparation are disclosed.

  结构式为 ##STR1## 的组胺H.sub.2-拮抗剂，其中p为1或2；R.sup.1为羟基，氨基，取代氨基或通过其氮原子连接的具有5-至9-成员完全饱和的含氮杂环环；m为0至2的整数；n为2至4的整数；Z为硫，氧或亚甲基；A为可选取代的苯基，咪唑基，噻唑基，异噻唑基，噁唑基，异噁唑基，三唑基，噻二唑基，氧杂二唑基，呋喃基，噻吩基或吡啶基环；以及其非毒性药学上可接受的盐，水合物，溶剂合物或N-氧化物是新型抗溃疡剂。公开了它们的中间体和制备方法。
• Pharmaceutical compositions
  申请人：Bristol-Myers Company

  公开号：EP0099121A2

  公开（公告）日：1984-01-25

  Enhanced antiulcer activity is obtained in warm-blooded animals by the concomitant administration of the pepsin complexing agent, pepstatin, and an histamine H2-receptor antagonist of the formula wherein A, m, Z, n, p and R1 are as defined herein. Concomitant administration of the two entities reduces the amount of histamine H2-receptor antagonist necessary for treatment, thereby decreasing its side-effect liability.

  在温血动物中，同时服用胃蛋白酶络合剂胃舒平和组胺 H2 受体拮抗剂，可增强抗溃疡活性。 其中 A、m、Z、n、p 和 R1 如本文所定义。同时使用这两种物质可减少治疗所需的组胺 H2 受体拮抗剂的用量，从而降低其副作用。